Virtual Meetings 2022

Meet The Professor: Optimizing the Management of HER2-Positive Breast Cancer

For an up-to-date schedule of upcoming sessions in this series, please click here.


Lisa A Carey, MD, ScM
L Richardson and Marilyn Jacobs Preyer
Distinguished Professor for Breast Cancer Research
Deputy Director for Clinical Sciences
Lineberger Comprehensive Cancer Center
University of North Carolina
Chapel Hill, North Carolina

Mark D Pegram, MD
Susy Yuan-Huey Hung Endowed Professor
of Oncology
Director, Clinical and Translational Research Unit
Associate Dean for Clinical Research Quality
Stanford University School of Medicine
Associate Director for Clinical Research
Stanford Comprehensive Cancer Institute
Stanford, California

Additional faculty to be announced.

Neil Love, MD
Research To Practice

These activities are supported by educational grants from Daiichi Sankyo Inc and Seagen Inc.


Each 1-hour session will be divided into topic modules focused on current management, emerging research and novel agents and strategies under active investigation for HER2-positive breast cancer. Each event will employ an identical format that will include the following elements:

  • Moderator Dr Neil Love and a featured participating clinical investigator
  • Discussion of participating faculty treatment recommendations
  • Review of available clinical research findings
  • Community oncologist video case presentations
  • Interactive audience polling and extensive Q&A

    MODULE 1: Optimal Management of HER2-Positive Localized Breast Cancer

    MODULE 2: Evolving Treatment Paradigm for Metastatic HER2-Positive Breast Cancer

    MODULE 3: Key Considerations in the Care of Patients with HER2-Positive Breast Cancer and Brain Metastasis

    MODULE 4: Monitoring for and Managing Toxicities Associated with Novel HER2-Directed Therapies

Target Audience
This program is intended for medical oncologists, hematologists, hematology-oncology fellows, radiation oncologists and other allied healthcare professionals involved in the treatment of breast cancer.

Learning Objectives

  • Appreciate the key clinical variables that affect the use of preoperative therapy and the selection of a specific neoadjuvant therapeutic regimen for patients with HER2-overexpressing localized breast cancer (BC), and integrate this information into treatment decision-making.
  • Apply available research evidence to individualize the selection and use of adjuvant systemic therapy for patients with HER2-positive localized BC who received neoadjuvant treatment.
  • Evaluate published research data to guide the selection and duration of adjuvant or extended-adjuvant therapy for patients with HER2-overexpressing localized BC.
  • Implement a long-term clinical plan for the management of advanced HER2-positive BC, considering recently presented clinical research findings and incorporating available and recently approved targeted agents and regimens.
  • Design an optimal approach to the care of patients with HER2-positive BC and central nervous system metastases, evaluating the implications of prior therapeutic exposure, symptomatology and other factors.
  • Recognize common and rare side effects associated with existing and recently approved anti-HER2 agents, and use this information to develop supportive management plans for patients undergoing treatment for HER2-positive BC.
  • Assess ongoing clinical research evaluating novel agents and treatment strategies under development for HER2-positive BC, and counsel patients regarding the potential benefits of trial participation.

CE Credit Form
CME and ABIM MOC credit form links will be emailed to each participant within 5 business days of the activity.

Accreditation Statement
Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Credit Designation Statement
Research To Practice designates each live activity for a maximum of 1 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

American Board of Internal Medicine (ABIM) — Maintenance of Certification (MOC)
Successful completion of each CME activity, which includes participation in the evaluation component and a short post-test, enables the participant to earn up to 1 Medical Knowledge MOC point in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Please note, this program has been specifically designed for the following ABIM specialty: medical oncology.

Personal information and data sharing: Research To Practice aggregates deidentified user data for program-use analysis, program development, activity planning and site improvement. We may provide aggregate and deidentified data to third parties, including commercial supporters. We do not share or sell personally identifiable information to any unaffiliated third parties or commercial supporters. Please see our privacy policy at for more information. For those clinicians wishing to receive ABIM MOC credit for attending, you will receive an email after the event with instructions.

Content Validation and Disclosures
Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education and adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of an accredited continuing education activity, including faculty, planners, reviewers and others, are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest will have been mitigated prior to the commencement of each activity. In addition, all activity content is reviewed by RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.

FACULTYDr Carey has no relevant conflicts of interest to disclose. The following faculty reported relevant financial relationships with ineligible entities:

Dr PegramAdvisory Committee: AstraZeneca Pharmaceuticals LP, bioTheranostics Inc, Daiichi Sankyo Inc, Genentech, a member of the Roche Group, Gilead Sciences Inc, Pfizer Inc, Sanofi Genzyme, Seagen Inc; Consulting Agreements: AstraZeneca Pharmaceuticals LP, bioTheranostics Inc, Daiichi Sankyo Inc, Genentech, a member of the Roche Group, Gilead Sciences Inc, Novartis, Pfizer Inc; Data and Safety Monitoring Board/Committee: AstraZeneca Pharmaceuticals LP.
Dr Mark Pegram’s contribution to this activity was as a paid consultant and was not part of his Stanford University duties or responsibilities.

SERIES MODERATORDr Love is president and CEO of Research To Practice. Research To Practice receives funds in the form of educational grants to develop CME activities from the following companies: AbbVie Inc, Adaptive Biotechnologies Corporation, ADC Therapeutics, Agios Pharmaceuticals Inc, Alexion Pharmaceuticals, Amgen Inc, Array BioPharma Inc, a subsidiary of Pfizer Inc, Astellas, AstraZeneca Pharmaceuticals LP, Aveo Pharmaceuticals, Bayer HealthCare Pharmaceuticals, BeiGene Ltd, BeyondSpring Pharmaceuticals Inc, Blueprint Medicines, Boehringer Ingelheim Pharmaceuticals Inc, Bristol-Myers Squibb Company, Celgene Corporation, Clovis Oncology, Coherus BioSciences, CTI BioPharma Corp, Daiichi Sankyo Inc, Eisai Inc, Elevation Oncology Inc, EMD Serono Inc, Epizyme Inc, Exact Sciences Corporation, Exelixis Inc, Five Prime Therapeutics Inc, Foundation Medicine, G1 Therapeutics Inc, Genentech, a member of the Roche Group, Genmab, Gilead Sciences Inc, GlaxoSmithKline, Grail Inc, Halozyme Inc, Helsinn Healthcare SA, ImmunoGen Inc, Incyte Corporation, Ipsen Biopharmaceuticals Inc, Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC, Jazz Pharmaceuticals Inc, Karyopharm Therapeutics, Kite, A Gilead Company, Lilly, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, MEI Pharma Inc, Merck, Mersana Therapeutics Inc, Mirati Therapeutics Inc, Natera Inc, Novartis, Novartis Pharmaceuticals Corporation on behalf of Advanced Accelerator Applications, Novocure Inc, Oncopeptides, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Puma Biotechnology Inc, Regeneron Pharmaceuticals Inc, Sanofi Genzyme, Seagen Inc, Servier Pharmaceuticals LLC, Sumitomo Dainippon Pharma Oncology Inc, Taiho Oncology Inc, Takeda Pharmaceuticals USA Inc, Tesaro, A GSK Company, TG Therapeutics Inc, Turning Point Therapeutics Inc, Verastem Inc and Zymeworks Inc.

RESEARCH TO PRACTICE CME PLANNING COMMITTEE MEMBERS, STAFF AND REVIEWERS — Planners, scientific staff and independent reviewers for Research To Practice have no relevant conflicts of interest to disclose.

These activities are supported by educational grants from Daiichi Sankyo Inc and Seagen Inc.